Cancer Vaccine Could Go ‘Above and Beyond Standard of Care’ For Patients
Source: CureToday, February 2024
Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.
The oncology community is on the cusp of a sea change regarding cancer vaccines, as one expert tells CURE®.
“Current vaccines have a dismal record, and minimal evidence of efficacy,” said Dr. Jeffrey S. Weber, deputy director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine, via email.